These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29349789)

  • 1. Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder.
    Harinstein L; Wu E; Brinker A
    Aliment Pharmacol Ther; 2018 Mar; 47(6):809-815. PubMed ID: 29349789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
    Gawron AJ; Bielefeldt K
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):378-384.e2. PubMed ID: 28804032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
    Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
    Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eluxadoline-induced pancreatitis occurring in an adult man without a prior cholecystectomy.
    Shahid Z; Packard E; Groff A; Jain R
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report.
    Chhaparia A; Hammami MB; Vareedayah A; Schroeder K
    Del Med J; 2017 Mar; 89(3):90-92. PubMed ID: 29894043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change.
    Cash BD; Lacy BE; Watton C; Schoenfeld PS; Weissman D
    Therap Adv Gastroenterol; 2021; 14():17562848211001725. PubMed ID: 33953798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder.
    Med Lett Drugs Ther; 2017 Apr; 59(1519):70. PubMed ID: 28419076
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical profile of acute pancreatitis following treatment with protease inhibitors: a real-world analysis of post-marketing surveillance data.
    Qin W; Zhao B; Shang Y; Zhang L
    Expert Opin Drug Saf; 2021 Sep; 20(9):1109-1115. PubMed ID: 34018864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
    Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
    Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
    N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
    Özdener AE; Rivkin A
    Drug Des Devel Ther; 2017; 11():2827-2840. PubMed ID: 29033544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review.
    Khetpal N; Yadav L; Khalid S; Kumar R
    Cureus; 2018 Dec; 10(12):e3747. PubMed ID: 30820368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.
    Swank KA; Wu E; Kortepeter C; McAninch J; Levin RL
    J Am Pharm Assoc (2003); 2017; 57(2S):S63-S67. PubMed ID: 28073687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
    Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
    Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.
    Raschi E; Piccinni C; Poluzzi E; Marchesini G; De Ponti F
    Acta Diabetol; 2013 Aug; 50(4):569-77. PubMed ID: 22008948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter: eluxadoline-associated acute pancreatitis-myth or reality?
    Garcia-Gonzalez F; Faghih M; Singh V
    Aliment Pharmacol Ther; 2018 Aug; 48(4):490-491. PubMed ID: 30588698
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: eluxadoline-associated acute pancreatitis-myth or reality? Authors' reply.
    Harinstein L; Wu E; Brinker A
    Aliment Pharmacol Ther; 2018 Aug; 48(4):491-492. PubMed ID: 30588693
    [No Abstract]   [Full Text] [Related]  

  • 18. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
    Keating GM
    Drugs; 2017 Jun; 77(9):1009-1016. PubMed ID: 28493170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline-related pancreatitis: a review of spontaneous adverse event reports.
    Okon E; Engell C; van Manen R; Brown J
    Pharmacotherapy; 2013 Jan; 33(1):63-8. PubMed ID: 23307547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
    Wittayanukorn S; Qian J; Johnson BS; Hansen RA
    J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.